Towarzystwo Funduszy Inwestycyjnych PZU SA’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-1,051
Closed -$56.9K – 684
2025
Q3
$56.9K Sell
1,051
-650
-38% -$37.2K 0.01% 385
2025
Q2
$93.5K Hold
1,701
– – 0.03% 262
2025
Q1
$120K Buy
1,701
+30
+2% +$2.02K 0.04% 204
2024
Q4
$110K Hold
1,671
– – 0.04% 195
2024
Q3
$117K Buy
1,671
+230
+16% +$19.2K 0.04% 181
2024
Q2
$119K Sell
1,441
-320
-18% -$26.6K 0.04% 162
2024
Q1
$154K Hold
1,761
– – 0.07% 139
2023
Q4
$170K Buy
+1,761
New +$156K 0.08% 108
2021
Q3
$65.5K Hold
848
– – 0.08% 105
2021
Q2
$70.8K Hold
848
– – 0.08% 106
2021
Q1
$64K Sell
848
-175
-17% -$14.3K 0.09% 103
2020
Q4
$89.7K Buy
+1,023
New +$81.1K 0.09% 74

Other funds holding BMRN

Towarzystwo Funduszy Inwestycyjnych PZU SA's BMRN Position: Q4 2025 in Review

Towarzystwo Funduszy Inwestycyjnych PZU SA sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 1,051 shares — an estimated $56.9K sold.

Towarzystwo Funduszy Inwestycyjnych PZU SA first reported a position in BMRN in Q4 2020 and held it in 12 quarters. The position peaked at $170K in Q4 2023. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Towarzystwo Funduszy Inwestycyjnych PZU SA reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Towarzystwo Funduszy Inwestycyjnych PZU SA sold 1,051 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $56.9K.
  • Towarzystwo Funduszy Inwestycyjnych PZU SA first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 12 quarters.
  • Towarzystwo Funduszy Inwestycyjnych PZU SA's BioMarin Pharmaceuticals position peaked at $170K in Q4 2023.
  • 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Towarzystwo Funduszy Inwestycyjnych PZU SA's 13F filing for Q4 2025, filed 13 Feb 2026.